Supplementary Table S5 from Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients

作者：Vivek Subbiah, Peter Paul Yu, Rangaprasad Sarangarajan, Michael A. Kiebish, Leonardo O. Rodrigues, Gregory M. Miller, Viatcheslav R. Akmaev, Shen Luan, John P. McCook, Nikunj Tanna, Tracey Reilly, Emily Chen, Valerie Bussberg, Shobha Ravipaty, Vivek K. Vishnudas, Stéphane Gesta, David Lucius, Can Bruce, Suwagmani Hazarika, Arianne Lyng, Allison Klotz, Vladimir Tolstikov, Janice R. Stevens, Victoria S. Chua, Elder Granger, Poornima K. Tekumalla, Ely Benaim, Vijay Modur, Marc S. Rudoltz, Paul Y. Song, Scott T. Tagawa, Andrew Hendifer, Sant P. Chawla, Manish A. Shah, David S. Hong, Ralph Zinner, Niven R. Narain, Madappa N. Kundranda · 年份：2025 · DOI：10.1158/2767-9764.30944109 · 研究领域：Cancer, Hypoxia, and Metabolism、Mitochondrial Function and Pathology、ATP Synthase and ATPases Research

<p>Treatment-emergent adverse events (TEAEs; all grades) that occurred in ≥10% of patients in any group treated with BPM31510IV.</p>